Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1514212

Cover Image

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1514212

Bioengineered Protein Drugs

PUBLISHED:
PAGES: 193 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Bioengineered Protein Drugs Market to Reach US$329.9 Billion by 2030

The global market for Bioengineered Protein Drugs estimated at US$245.5 Billion in the year 2023, is expected to reach US$329.9 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2023-2030. Therapeutic Proteins, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$129.2 Billion by the end of the analysis period. Growth in the Monoclonal Antibodies segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$66.2 Billion While China is Forecast to Grow at 7.2% CAGR

The Bioengineered Protein Drugs market in the U.S. is estimated at US$66.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$69.4 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Bioengineered Protein Drugs - Key Trends and Drivers

Bioengineered protein drugs, also known as biopharmaceuticals, have revolutionized the field of medicine, offering targeted and effective treatments for a wide range of diseases. These drugs are developed using advanced genetic engineering techniques that allow for the production of proteins identical to those naturally occurring in the human body. These proteins can be designed to interact with specific biological pathways, enabling precise intervention in disease mechanisms. Examples include monoclonal antibodies, used in cancer therapy, and insulin analogs for diabetes management. The complexity of their development, involving recombinant DNA technology and rigorous purification processes, ensures high specificity and efficacy, distinguishing them from traditional small-molecule drugs. As a result, bioengineered protein drugs have become a cornerstone in treating chronic conditions such as rheumatoid arthritis, multiple sclerosis, and various types of cancers.

The regulatory landscape for bioengineered protein drugs is stringent, reflecting the need for ensuring safety and efficacy given their biological origin and complexity. The approval process typically involves extensive clinical trials and post-marketing surveillance to monitor adverse effects and long-term outcomes. Innovations in biotechnology, such as CRISPR and other gene-editing tools, have further accelerated the development of these drugs, enabling more precise modifications and potentially reducing development times. Moreover, advancements in bioprocessing and manufacturing techniques have improved the scalability and cost-effectiveness of producing bioengineered proteins. As these technologies evolve, the pipeline of bioengineered protein drugs continues to expand, addressing unmet medical needs and offering new hope for patients with previously untreatable conditions.

The growth in the bioengineered protein drugs market is driven by several factors, including technological advancements, increased prevalence of chronic diseases, and growing acceptance and demand for personalized medicine. Technological innovations have streamlined the drug development process, reducing costs and time-to-market, while biopharmaceutical companies are leveraging these advancements to develop more potent and targeted therapies. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders has also heightened the demand for these advanced treatments. Furthermore, consumer behavior trends indicate a strong preference for personalized medicine, which bioengineered proteins are uniquely positioned to deliver due to their ability to be tailored to individual genetic profiles. Additionally, favorable regulatory policies and increased healthcare funding in many regions are supporting the rapid market expansion. Investment in research and development by both private and public sectors is also pivotal, driving continuous innovation and the introduction of next-generation biopharmaceuticals.

Select Competitors (Total 56 Featured) -

  • Abbott India Ltd.
  • Amgen, Inc.
  • Bayer AG
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Panacea Biotec Ltd.
  • ProBioGen AG
Show more
Product Code: MCP-6377

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Bioengineered Protein Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Genetic Engineering Propel Growth in Bioengineered Protein Drugs Market
    • Increasing Prevalence of Chronic Diseases Expands Addressable Market Opportunity
    • Personalized Medicine Trends Strengthen Business Case for Bioengineered Proteins
    • Innovations in Bioprocessing Technologies Drive Cost-Efficiency and Scalability
    • Rising Consumer Demand for Targeted Therapies Generates Opportunities
    • Adoption of CRISPR and Gene-Editing Tools Accelerates Development Timelines
    • Healthcare Funding Increases Propel Market Adoption
    • Enhanced Purification Techniques Improve Drug Safety and Efficacy
    • Advanced Manufacturing Technologies Enhance Production Capabilities
    • Post-Marketing Surveillance Strengthens Confidence in Bioengineered Protein Drugs
    • Technological Synergies with Digital Health Tools Enhance Treatment Outcomes
    • Novel Drug Delivery Systems Expand Therapeutic Applications
    • Data Analytics and AI Integration Improve Drug Development Efficiency
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bioengineered Protein Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bioengineered Protein Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Therapeutic Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Academics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • JAPAN
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • CHINA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • EUROPE
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Bioengineered Protein Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • FRANCE
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • GERMANY
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Bioengineered Protein Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • INDIA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Bioengineered Protein Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Bioengineered Protein Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • AFRICA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!